Enterprises need to invest as much in their data as they do in their AI technology to drive tangible, measurable results.

In a proof-of-concept study, the CMRI team has discovered two novel AAV capsids, known as AAV-T1 and AAV-T2, which can produce therapeutic CAR T cells using a five-fold lower dose of the vector.

Collaborative project with world leader in AI computing demonstrates Artificial workflows and model integration for self-driving generative virtual screening in drug discovery. Company also announces ...

Professor Simon Stellmer from the University of Bonn receives a ‘Proof of Concept Grant’ from the European Research Council (ERC) for his project „GyroRevolutionPlus“. With the funding of €150,000 for ...

First demonstration of single AAV muscle editing in non-human primates: NanoCas achieved in vivo editing efficiencies of up to 30% when targeting dystrophin in the skeletal muscle of cynomolgus ...